Wednesday, June 10, 2026
🇺🇸 FDA

pharma

Amarin Neuroscience

Amarin Neuroscience Ltd

NovaPharmaNews editorial coverage mentioning Amarin Neuroscience — regulatory, clinical, and market analysis.

GB HQ
EMA registrant Type
Company details
Status
Public
HQ
GB
Programs
0
Drugs
0
Patents
11
Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Coverage

News & analysis

NovaPharmaNews articles mentioning Amarin Neuroscience — regulatory, clinical, and market coverage.

NovaPharmaNews editorial coverage mentioning Amarin Neuroscience — regulatory, clinical, and market analysis.

All News Analysis

1 articles

STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
Critical impact AnalysisJun 5, 2026

STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors

Supreme Court · 6 min

The U.S. Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents through its skinny-labeled generic version of Vascepa. This decision clarifies the Hatch-Waxman skinny-label safe harbor, reducing litigation risk for generic entrants and reshaping competitive dynamics for branded cardiovascular drugs.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.